Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delamanid + bedaquiline + OPC-167832
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination regimen of three small molecule drugs—delamanid, bedaquiline, and OPC-167832—under investigation for the treatment of tuberculosis (TB), including drug-susceptible and multidrug-resistant forms. - **Delamanid** (brand name DELTYBA) inhibits mycolic acid synthesis in *Mycobacterium tuberculosis* cell walls. - **Bedaquiline** (brand name SIRTURO) targets the ATP synthase enzyme essential for mycobacterial energy production. - **OPC-167832** (also known as quabodepistat) is a novel carbostyril derivative that inhibits decaprenylphosphoryl-beta-D-ribose 2'-oxidase (DprE1), an enzyme critical to cell wall biosynthesis in *M. tuberculosis*[1][2][3][4]. This combination aims to provide potent bactericidal activity with potential to shorten TB treatment duration and improve outcomes compared to standard regimens[2][3]. The regimen is currently being evaluated in clinical trials for safety and efficacy in drug-susceptible pulmonary TB[7].
- Brand names
- deltybasirturo
- Other names
- quabodepistat
02
Targets
DprE1 (Decaprenylphosphoryl-beta-D-ribose oxidase)AtpE (ATP synthase subunit c of Mycobacterium tuberculosis)InhA
Beyond the preview
Go deeper on delamanid + bedaquiline + OPC-167832.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delamanid + bedaquiline + OPC-167832.